Protagonist Therapeutics (NASDAQ: PTGX) updates corporate presentation

Rhea-AI Filing Summary

Protagonist Therapeutics, Inc. reported that it has made an updated corporate presentation available as of January 12, 2026. The presentation is provided as Exhibit 99.1 to a current report on Form 8-K under Regulation FD, which is intended to share information broadly with the market. The company notes that this information, including the exhibit, is being furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.

false 0001377121 0001377121 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

PROTAGONIST THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37852		98-0505495
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Protagonist Therapeutics, Inc. 

7707 Gateway Blvd., Suite 140

Newark, California 94560-1160

(Address of principal executive offices, including zip code)

(510) 474-0170

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001		PTGX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On January 12, 2026, Protagonist Therapeutics, Inc. (the “Company”) made available an updated corporate presentation. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01  Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Protagonist Therapeutics, Inc. Corporate Presentation, as of January 12, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Protagonist Therapeutics, Inc.
Dated: January 12, 2026
	By:	/s/ Asif Ali
		Asif Ali
		Chief Financial Officer

FAQ

What did Protagonist Therapeutics (PTGX) disclose in the latest 8-K?

Protagonist Therapeutics disclosed that it made an updated corporate presentation available on January 12, 2026, furnished as Exhibit 99.1 to a Form 8-K under Regulation FD.

When is the Protagonist Therapeutics corporate presentation dated?

The corporate presentation for Protagonist Therapeutics is described as being as of January 12, 2026.

How is the Protagonist Therapeutics corporate presentation furnished to investors?

The presentation is included as Exhibit 99.1 to a Form 8-K, made available under Item 7.01 Regulation FD Disclosure.

Is the Protagonist Therapeutics (PTGX) presentation considered filed with the SEC?

No. The company states that the information in this report, including the exhibit, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or Section 11 and 12(a)(2) of the Securities Act.

Will the Protagonist Therapeutics corporate presentation be incorporated by reference into other SEC filings?

The company specifies that the information contained in the report and exhibit shall not be incorporated by reference into any other SEC filing, regardless of general incorporation language in such filings.

Who signed the Protagonist Therapeutics Form 8-K for the corporate presentation?

The Form 8-K was signed on behalf of Protagonist Therapeutics, Inc. by Asif Ali, who is identified as the Chief Financial Officer.